Clinical Trial Detail

NCT ID NCT02635074
Title Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Steven E. Coutre
Indications

acute myeloid leukemia

Therapies

Cytarabine + Ibrutinib + Idarubicin

Age Groups: adult

No variant requirements are available.